Nuo Therapeutics, Inc. financial data

Symbol
AURX on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
8285 El Rio, Suite 150, Houston, TX
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CYTOMEDIX INC (to 10/8/2014), AUTOLOGOUS WOUND THERAPY INC (to 4/10/2000), AUTOLOGOUS WOUND TRERAPY INC (to 3/23/2000)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 177 % -52.5%
Quick Ratio 30.1 % -23.5%
Debt-to-equity 128 % +171%
Return On Equity -399 % -98.3%
Return On Assets -175 % -28.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 45.5M shares +7.44%
Common Stock, Shares, Outstanding 45.5M shares +8.77%
Entity Public Float 35.9M USD +102%
Common Stock, Value, Issued 4.55K USD +8.78%
Weighted Average Number of Shares Outstanding, Basic 44.7M shares +6.84%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -2.69M USD +25.2%
Nonoperating Income (Expense) 1.89K USD
Net Income (Loss) Attributable to Parent -2.69M USD +25.2%
Earnings Per Share, Basic -0.07 USD/shares +22.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 473K USD +37.4%
Accounts Receivable, after Allowance for Credit Loss, Current 305K USD +51.4%
Inventory, Net 217K USD -3.98%
Assets, Current 1.17M USD +15.2%
Property, Plant and Equipment, Net 41.6K USD -17.7%
Operating Lease, Right-of-Use Asset 204K USD -35.2%
Assets 1.42M USD +2.54%
Accounts Payable, Current 398K USD -8.83%
Accrued Liabilities, Current 230K USD +26.5%
Liabilities, Current 690K USD -1.86%
Operating Lease, Liability, Noncurrent 132K USD -37.6%
Liabilities 822K USD -10.1%
Retained Earnings (Accumulated Deficit) -31.2M USD -9.45%
Stockholders' Equity Attributable to Parent 599K USD +27.1%
Liabilities and Equity 1.42M USD +2.54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -562K USD +29.3%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 45.5M shares +8.77%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -562K USD +29.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 473K USD +18.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21K USD +63.7%
Deferred Tax Assets, Valuation Allowance 41.3M USD -0.91%
Deferred Tax Assets, Gross 41.3M USD -0.91%
Operating Lease, Liability 194K USD -34.5%
Depreciation 15K USD +12.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 223K USD -36.6%
Property, Plant and Equipment, Gross 459K USD +1.33%
Operating Lease, Liability, Current 62.4K USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 82.7K USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 80.3K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.1K USD -47.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.3K USD -74.3%
Deferred Tax Assets, Operating Loss Carryforwards 40.9M USD -0.77%
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 21.3K USD -74.3%
Additional Paid in Capital 31.8M USD +9.74%
Share-based Payment Arrangement, Expense 23.1K USD +53547%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%